| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2023 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 50,000 | $30.00 | $1,500,000.00 | -85.6% | -30.2% | -91.5% | |
| Jan 20, 2023 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | Chief Medical Officer | Sell | 29,713 | $30.00 | $891,390.00 | -100% | -30.2% | -91.5% | |
| Jan 19, 2023 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $258.95 | $1,553,683.20 | -5.0% | -12.8% | -16.2% | |
| Jan 19, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $259.83 | $4,157,220.77 | -54.6% | -12.8% | -16.2% | |
| Jan 18, 2023 | ESPR Esperion Therapeutics, Inc. | Looker Benjamin48 | General Counsel | Sell | 6,347 | $7.00 | $44,403.61 | -9.0% | -80.6% | -68.4% | |
| Jan 18, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 4,936 | $40.40 | $199,394.16 | -0.6% | -9.8% | -31.6% | |
| Jan 18, 2023 | ESPR Esperion Therapeutics, Inc. | Foody Joanne M.73 | Chief Medical Officer | Sell | 1,191 | $6.99 | $8,319.14 | -1.1% | -80.6% | -68.4% | |
| Jan 17, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 25,446 | $40.03 | $1,018,728.07 | -3.1% | -8.3% | -30.4% | |
| Jan 17, 2023 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 386 | $52.97 | $20,446.42 | -0.6% | +65.0% | +2.3% | |
| Jan 17, 2023 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,000 | $7.51 | $15,020.00 | -0.7% | +29.8% | +9.5% | |
| Jan 17, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 4,826 | $39.92 | $192,637.99 | -74.6% | -8.3% | -30.4% | |
| Jan 17, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $261.01 | $4,176,164.97 | -45.6% | -11.8% | -14.9% | |
| Jan 13, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | Director, 10% Owner | Buy | 6,010,000 | $0.01 | $30,310.00 | +4.0% | - | - | |
| Jan 12, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $261.82 | $4,189,174.58 | -31.0% | -13.7% | -16.3% | |
| Jan 10, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $265.69 | $4,251,024.43 | -26.4% | -15.3% | -15.8% | |
| Jan 9, 2023 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 17,834 | $27.39 | $488,553.97 | -5.3% | -15.2% | +15.7% | |
| Jan 9, 2023 | MRK Merck & Co., Inc. | Chattopadhyay Sanat | Exe V-p &Pres. Mmd | Sell | 83,994 | $112.29 | $9,431,915.24 | -23.0% | +2.7% | +10.3% | |
| Jan 6, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Yeramian Patrick D84 | Chief Medical Officer | Sell | 2,034 | $36.30 | $73,831.01 | -0.5% | -21.4% | -54.5% | |
| Jan 6, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 2,658 | $36.30 | $96,481.25 | -3.7% | -21.4% | -54.5% | |
| Jan 6, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 5,968 | $36.30 | $216,629.35 | -0.1% | -21.4% | -54.5% | |
| Jan 6, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 5,968 | $36.30 | $216,629.35 | -0.1% | -21.4% | -54.5% | |
| Jan 6, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Olinger Margaret | Chief Commercial Officer | Sell | 2,403 | $36.30 | $87,225.05 | -0.6% | -21.4% | -54.5% | |
| Jan 6, 2023 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 400 | $125.00 | $50,000.00 | -2.5% | -14.8% | +7.7% | |
| Jan 6, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 174 | $39.90 | $6,942.60 | -9.6% | -5.8% | -30.3% | |
| Jan 6, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $274.82 | $4,397,087.74 | -28.4% | -17.7% | -16.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.